Trial Profile
A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms LenCombo
- Sponsors Sanofi
- 12 Jul 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2023 Planned End Date changed from 9 May 2023 to 20 Jun 2023.
- 20 Apr 2023 Planned primary completion date changed from 9 May 2023 to 20 Jun 2023.